1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Prostate Cancer Treatment Market
2.2. Global Prostate Cancer Treatment Market, By Treatment, 2023 (US$ Million)
2.3. Global Prostate Cancer Treatment Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Prostate Cancer Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Prostate Cancer Treatment Market Vendors
3.2. Strategies Adopted by Prostate Cancer Treatment Market Vendors
3.3. Key Industry Strategies
4. Prostate Cancer Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Prostate Cancer Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Biological Therapy
5.3.1.1. Enzalutamid
5.3.1.2. Abiraterone
5.3.1.3. Leuprolide
5.3.1.4. Goserelin
5.3.1.5. Triptorelin
5.3.1.6. Histrelin
5.3.1.7. Degarelix
5.3.1.8. Sipuleucel-T
5.3.2. Chemotherapy
5.3.2.1. Mitotic inhibitors e.g. Docetaxel, Cabazitaxel
5.3.2.2. Topoisomerase inhibitors e.g. Mitoxantrone
5.3.2.3. Alkylating antineoplastic agent e.g. Estramustine


6. North America Prostate Cancer Treatment Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
6.3.Prostate Cancer Treatment Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)

7. UK and European Union Prostate Cancer Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.Prostate Cancer Treatment Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)

8. Asia Pacific Prostate Cancer Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.Prostate Cancer Treatment Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)

9. Latin America Prostate Cancer Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
9.3.Prostate Cancer Treatment Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)

10. Middle East and Africa Prostate Cancer Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
10.3.Prostate Cancer Treatment Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Prostate Cancer Treatment Market: By Treatment, 2022-2032, USD (Million)

11. Company Profile
11.1. Tolmar Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Astellas Pharma, Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. AstraZeneca Plc
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Ferring Pharmaceuticals
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Johnson & Johnson
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Abbott Laboratories
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Sanofi
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Ipsen
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Novartis
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Bayer Healthcare Pharmaceuticals, Inc
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives